Blinatumomab (CD3 × B lymphocyte antigen CD19) has been utilized to treat B-cell acute lymphocytic leukemia with impressive clinical results, and more than 50 bsAbs are currently being evaluated for the treatment of hematological and solid tumors48. The gene discussed is AKAP17A; the disease is precursor B-cell acute lymphoblastic leukemia.